



(11) **EP 4 025 212 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
16.04.2025 Bulletin 2025/16

(45) Date of publication and mention
of the grant of the patent:
26.02.2025 Bulletin 2025/09

(21) Application number: **20867155.2**

(22) Date of filing: **25.09.2020**

(51) International Patent Classification (IPC):
A61K 31/4245^(2006.01) C07D 413/04^(2006.01)
A61P 31/16^(2006.01)

(52) Cooperative Patent Classification (CPC):
C07D 413/12; A61K 31/4245; A61K 45/06;
A61P 31/16; Y02A 50/30

(86) International application number:
PCT/US2020/052773

(87) International publication number:
WO 2021/062189 (01.04.2021 Gazette 2021/13)

(54) **ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AND THEIR USE FOR TREATMENT OF DISEASES CAUSED BY VIRUS INFECTION**

ISOXAZOL-3-CARBOXAMIDDERIVATE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON DURCH VIRUSINFEKTION VERURSACHTEN KRANKHEITEN

DÉRIVÉS D'ISOXAZOLE-3-CARBOXAMIDE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES PROVOQUÉES PAR UNE INFECTION VIRALE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: **27.09.2019 US 201962907231 P**
19.12.2019 US 201962950546 P

(43) Date of publication of application:
13.07.2022 Bulletin 2022/28

(73) Proprietors:
• **Collaborations Pharmaceuticals, Inc.**
Raleigh, NC 27606 (US)
• **Universitätsklinikum Jena**
07747 Jena (DE)

(72) Inventors:
• **MAKAROV, Vadim**
Moscow, 115035 (RU)
• **SCHMIDTKE, Michaela**
07745 Jena (DE)

• **EKINS, Sean**
Fuquay Varina, NC 27526 (US)

(74) Representative: **Isarpatent**
Patent- und Rechtsanwälte Barth
Charles Hassa Peckmann & Partner mbB
Friedrichstrasse 31
80801 München (DE)

(56) References cited:
US-A1- 2011 065 764 US-A1- 2012 095 002
US-A1- 2019 054 068

• **MAKAROV VADIM A. ET AL: "Novel**
[(biphenyloxy)propyl]isoxazole derivatives for
inhibition of human rhinovirus 2 and
coxsackievirus B3 replication", JOURNAL OF
ANTIMICROBIAL CHEMOTHERAPY, vol. 55, no.
4, 1 April 2005 (2005-04-01), GB, pages 483 - 488,
XP093060461, ISSN: 0305-7453, Retrieved from
the Internet <URL:https://academic.oup.com/jac/
article-pdf/55/4/483/2399776/dki055.pdf> DOI:
10.1093/jac/dki055

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 4 025 212 B8

- | | |
|---|---|
| <ul style="list-style-type: none"> • SCHMIDTKE M ET AL: "New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 81, no. 1, 1 January 2009 (2009-01-01), pages 56 - 63, XP025761847, ISSN: 0166-3542, [retrieved on 20081208], DOI: 10.1016/J.ANTIVIRAL.2008.09.002 • CHEN YONGSHENG ET AL: "[alpha]Gal-conjugated anti-rhinovirus agents: chemo-enzymatic syntheses and testing of anti-Gal binding", ROYAL CHEMICAL SOCIETY. JOURNAL. PERKIN TRANSACTIONS 1, no. 14, 1 January 2001 (2001-01-01), GB, pages 1716 - 1722, XP093060427, ISSN: 1472-7781, DOI: 10.1039/b100356i | <ul style="list-style-type: none"> • DATABASE PubChem Compound 3 May 2011 (2011-05-03), ANONYMOUS: "Compound Summary for CID 51323276", XP055806868, retrieved from NCBI Database accession no. CID 51323276 |
|---|---|